OncoMatch/Clinical Trials/NCT07024784
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Is NCT07024784 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including IMGN151 and Carboplatin for gynecologic cancers.
Treatment: IMGN151 · Carboplatin · Bevacizumab · Olaparib — Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: FRα-targeting therapy
Prior treatment with FRα-targeting therapy
Cannot have received: wide-field radiotherapy affecting more than 20% of the bone marrow
Prior wide-field radiotherapy affecting more than 20% of the bone marrow
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Holy Name Medical Center /ID# 279017 · Teaneck, New Jersey
- Providence Portland Medical Center /ID# 277727 · Portland, Oregon
- Women & Infants Hospital /ID# 277930 · Providence, Rhode Island
- SCRI Oncology Partners /ID# 279733 · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify